Doxorubicin

BNF:

8.1.2

Status:

Red

Decision Date:

May 2016

Comments

RED:

NICE TA389: pegylated liposomal doxorubicin hydrochloride is recommended as an option for treating recurrent ovarian cancer.  (Decision date - May 2016).

NHS England drug - to be used in line with NHS England commissioning intentions.

 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again